PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine Inc. is positioned for significant financial growth, with projections indicating that PM577 could generate risk-adjusted revenues of $980 million by 2035, rising from $32 million in 2030. The company is advancing its drug candidate PM577 for Wilson’s Disease, with expectations of an IND/CTA filing in the first half of 2026, suggesting a favorable commercial opportunity backed by strong preclinical data. Additionally, ongoing developments in gene editing and the potential positive readouts from clinical data in related technologies may further enhance investor interest and confidence in Prime Medicine's in vivo gene editing capabilities.
Bears say
The outlook for Prime Medicine's stock is negatively influenced by the potential challenges in regulatory approval for its gene editing therapies, which could lead to downward revisions of revenue projections. Additionally, recruitment difficulties for eligible patients in clinical programs may hinder the overall progress and success of its product pipeline. Finally, concerns regarding the affordability of Prime’s therapies in the market and safety risks associated with gene editing technologies further exacerbate the financial uncertainties facing the company.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares